Clinical Report: Linking Tumor Genomic Alterations to Hypophysitis Risk from PD-1 Inhibitors
Overview
This study identifies a higher tumor mutational burden and specific gene mutations in patients with hypophysitis induced by PD-1 inhibitors.
Background
Immune checkpoint inhibitors (ICIs) have transformed cancer treatment but can lead to serious immune-related adverse events (irAEs), including hypophysitis. This endocrine toxicity can result in significant complications such as adrenal crisis, necessitating hormone replacement therapy. Understanding the genomic factors associated with hypophysitis is crucial for risk stratification and management of patients undergoing ICI therapy.
Data Highlights
Group
Tumor Mutational Burden (mut/Mb)
Significant Mutations
Hypophysitis
6.02
BABAM1, KDM5C, CDH4, TAL1
Non-Hypophysitis
5.19
PAXIP1
Key Findings
The hypophysitis group exhibited a higher tumor mutational burden (6.02 vs. 5.19 mut/Mb, P = 0.002).
Significantly higher mutation rates were observed in BABAM1 (18.2% vs. 0%, P = 0.014) and KDM5C (18.2% vs. 0%, P = 0.014) in the hypophysitis group.
CDH4 mutations were more prevalent in the hypophysitis group (19.2% vs. 1.8%, P = 0.018).
TAL1 mutations were also significantly higher in the hypophysitis group (19.2% vs. 1.8%, P = 0.018).
PAXIP1 mutations were more common in the non-hypophysitis group (19.6% vs. 0%, P = 0.037), indicating a potential protective role.
Clinical Implications
The findings suggest that tumor genomic profiling may aid in identifying patients at higher risk for developing hypophysitis during PD-1 inhibitor therapy. Clinicians should consider monitoring these patients closely for endocrine complications.
Conclusion
This study provides insights into the genomic factors associated with PD-1 inhibitor-induced hypophysitis.
